Virus Clinical Trial
Official title:
Herpes Simplex Virus-1: A Pilot Study Using Hand Sanitizer
The purpose of this pilot study is to determine if the use of Purell hand sanitizer alters the duration, level of pain and discomfort during treatment, and the size of the HSV-1 lesion. The duration of an HSV-1 (herpes) lesion is the primary endpoint for this study. Size, pain, and discomfort are the secondary endpoints.
The participants will be divided into a control group (10 participants) and treatment group (10 participants) and will be given either the Purell hand sanitizer (treatment group) or medical grade mineral oil (control group) to treat the lesion. Participants will apply a large drop of the product (purell hand sanitizer or mineral oil) on a q-tip and will hold the q-tip on the lesion for 10 seconds. Participants will be instructed to apply a solution to lesion every waking hour for the next 14 days or until lesion has healed. Each day the participant will fill out the daily journal. The journal includes a measurement in millimeters of the lesion with graph paper, recorded number of applications for that day, and two visual analog scales- one measuring any discomfort from the lesion and the other recording the pain during the application process. Documentation of changes to the lesion will be recorded in a daily journal until the lesion is healed. There are two days that the participants are expected to return to the clinic for re-examination at day three and the last day when the lesion has healed, or the crust has fallen off. Pictures of the lesion will taken at these two points in time. The duration the HSV-1 lesion, level of pain and discomfort during treatment, and the size of the HSV-1 lesion will be statistically measured between the control group (mineral oil) and the treatment group (purell hand sanitizer) to determine if there is any statistical difference between the two groups. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03911388 -
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
|
Phase 1 | |
| Recruiting |
NCT06059027 -
Microbes and Respiratory Illnesses
|
||
| Recruiting |
NCT03463694 -
Edinburgh and Lothian Virus Intervention Study in Kids
|
N/A | |
| Recruiting |
NCT04393415 -
Using PRP and Cord Blood in Treatment of Covid -19
|
N/A | |
| Not yet recruiting |
NCT05387226 -
Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT05064462 -
TTV Viral Load in Heart Transplant Recipients
|
||
| Recruiting |
NCT04336020 -
The DETECT(Digital Engagement & Tracking for Early Control, & Treatment) Study
|
||
| Recruiting |
NCT05727709 -
Dynamic Changes of Torquetenovirus (TTV) Load in Chinese Renal Transplant Recipients
|
||
| Recruiting |
NCT04382131 -
Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19)
|
N/A | |
| Completed |
NCT02743663 -
The Development of Novel Clinical Tests to Diagnose and Monitor Asthma in Preschool Children
|
||
| Not yet recruiting |
NCT05868551 -
Onchocerciasis-Associated Epilepsy, an Explorative Case-control Study
|
||
| Completed |
NCT01136395 -
Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation
|
Phase 2 | |
| Completed |
NCT01159561 -
Western Equine Encephalitis Vaccine, Inactivated
|
Phase 1 | |
| Completed |
NCT04636294 -
Borderline COVID-19 PCR Test Result
|
||
| Recruiting |
NCT04449978 -
TARGet Kids! COVID-19 Study of Children and Families
|
||
| Recruiting |
NCT04348864 -
COVID-19 Diagnostic Self-testing Using Virtual Point-of-care
|
N/A |